In high-income countries (HICs), clinical outcomes for patients with severe COVID-19 have improved substantially over time, in part due to targeted administration of immunomodulatory therapeutics (i.e., corticosteroids, interleukin-6 and JAK1/2 antagonists) and widespread SARS-CoV-2 vaccine uptake2–7. This evidence concerns the gene IL6 and COVID-19.